GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Cirrhosis Liver/Prediction of the Risk of Developing Severe Liver Disease
101

Prediction of the Risk of Developing Severe Liver Disease

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated October 1, 2025

The CORE model, developed by researchers at Karolinska Institutet, predicts the 10-year risk of developing severe liver diseases, such as cirrhosis and liver cancer, using a simple blood test. It combines three routinely measured liver enzyme levels (AST, ALT, GGT) with age and sex. The model demonstrated 88% predictive accuracy, outperforming the widely used FIB-4 method, and is particularly suited for primary care settings. Validated in cohorts from Finland and the UK, it is accessible via a web-based calculator (www.core-model.com). Further testing among high-risk groups is needed, and efforts are underway to integrate it into electronic medical record systems for streamlined clinical use.

Related Q&A

102

Antibiotics prophylaxis in GI bleeding in Cirrhosis Liver

Antibiotic Prophylaxis in Gastrointestinal (GI) Bleeding in Cirrhosis: A Comprehensive Overview Antibiotic prophylaxis has been a cornerstone in the management of cirrhotic patients with upper gastrointestinal (GI) bleeding...

103

Ultra-early (16 years) predictive model for MASLD

The ultra-early predictive model for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) is a promising development in preventive healthcare. This model relies on identifying specific protein changes in the...

104

Hepatic recompensation in patients with decompensated cirrhosis – What is new?

Hepatic recompensation in patients with decompensated cirrhosis has emerged as a transformative concept in liver disease management, challenging the long-held belief that cirrhosis is irreversible. Recent advancements have...

105

Acute variceal bleeding in patients with cirrhosis and portal hypertension- APASL 2025

The management of acute variceal bleeding (AVB) in patients with cirrhosis and portal hypertension has been updated in the Asia-Pacific Association for the Study of the Liver (APASL)...

106

Systemic therapies in patients HCC who also have advanced liver dysfunction (Child-Pugh class B)

GastroAGIDashboardDocumentsUpload DocumentsUsersUser ActivityRecent ChatSections ManageCustom QuestionsEmail TemplateConferenceGastroAGICirrhosis Liver2025NovemberClinical Challenge: Most pivotal HCC trials excluded Child-Pugh B patients, so systemic therapy in this group remains controversial. This leaves a...

01

Breath-Based Sensor (LivSens) Shows Promise for Screening HE: JHE | August 2026

Hepatic encephalopathy (HE) is usually diagnosed through clinical assessment and psychometric testing, but these approaches can be time-consuming and require trained personnel. LivSens is a portable multisensor breath-analysis...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer